Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3).

Abstract:

:Mucormycosis is an emerging cause of infectious morbidity and mortality in patients with hematologic malignancies. However, there are no recommendations to guide diagnosis and management. The European Conference on Infections in Leukemia assigned experts in hematology and infectious diseases to develop evidence-based recommendations for the diagnosis and treatment of mucormycosis. The guidelines were developed using the evidence criteria set forth by the American Infectious Diseases Society and the key recommendations are summarized here. In the absence of validated biomarkers, the diagnosis of mucormycosis relies on histology and/or detection of the organism by culture from involved sites with identification of the isolate at the species level (no grading). Antifungal chemotherapy, control of the underlying predisposing condition, and surgery are the cornerstones of management (level A II). Options for first-line chemotherapy of mucormycosis include liposomal amphotericin B and amphotericin B lipid complex (level B II). Posaconazole and combination therapy of liposomal amphotericin B or amphotericin B lipid complex with caspofungin are the options for second line-treatment (level B II). Surgery is recommended for rhinocerebral and skin and soft tissue disease (level A II). Reversal of underlying risk factors (diabetes control, reversal of neutropenia, discontinuation/taper of glucocorticosteroids, reduction of immunosuppressants, discontinuation of deferroxamine) is important in the treatment of mucormycosis (level A II). The duration of antifungal chemotherapy is not defined but guided by the resolution of all associated symptoms and findings (no grading). Maintenance therapy/secondary prophylaxis must be considered in persistently immunocompromised patients (no grading).

journal_name

Haematologica

journal_title

Haematologica

authors

Skiada A,Lanternier F,Groll AH,Pagano L,Zimmerli S,Herbrecht R,Lortholary O,Petrikkos GL,European Conference on Infections in Leukemia.

doi

10.3324/haematol.2012.065110

subject

Has Abstract

pub_date

2013-04-01 00:00:00

pages

492-504

issue

4

eissn

0390-6078

issn

1592-8721

pii

haematol.2012.065110

journal_volume

98

pub_type

杂志文章,实务指引,评审
  • Diabetes and the risk of non-Hodgkin's lymphoma and multiple myeloma in the European Prospective Investigation into Cancer and Nutrition.

    abstract:BACKGROUND:Non-Hodgkin's lymphomas are a heterogeneous group of neoplasms arising from the lymphopoietic system including a wide range of subtypes of either B-cell or T-cell lymphomas. The few established risk factors for the development of these neoplasms include viral infections and immunological abnormalities, but t...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.12297

    authors: Khan AE,Gallo V,Linseisen J,Kaaks R,Rohrmann S,Raaschou-Nielsen O,Tjønneland A,Johnsen HE,Overvad K,Bergmann MM,Boeing H,Benetou V,Psaltopoulou T,Trichopoulou A,Masala G,Mattiello A,Grioni S,Tumino R,Vermeulen RC,Pe

    更新日期:2008-06-01 00:00:00

  • A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.

    abstract::Sixteen patients with stage III multiple myeloma (MM) and a median age of 51 years were treated with autografting followed by reduced intensity conditioning allotransplantation (RICT). Nine patients are alive in remission at a median of 30 months after their transplants, one patient is alive in relapse and 6 patients ...

    journal_title:Haematologica

    pub_type: 临床试验,信件

    doi:

    authors: Carella AM,Beltrami G,Corsetti MT,Scalzulli P,Carella AM Jr,Musto P

    更新日期:2004-12-01 00:00:00

  • Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells.

    abstract::Leukemia stem cells contribute to drug-resistance and relapse in chronic myeloid leukemia (CML) and BCR-ABL1 inhibitor monotherapy fails to eliminate these cells, thereby necessitating alternate therapeutic strategies for patients CML. The peroxisome proliferator-activated receptor-γ (PPARγ) agonist pioglitazone downr...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.194910

    authors: Kumar H,Chattopadhyay S,Das N,Shree S,Patel D,Mohapatra J,Gurjar A,Kushwaha S,Singh AK,Dubey S,Lata K,Kushwaha R,Mohammed R,Dastidar KG,Yadav N,Vishwakarma AL,Gayen JR,Bandyopadhyay S,Chatterjee A,Jain MR,Tripathi

    更新日期:2020-04-01 00:00:00

  • IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study.

    abstract::Patients with chronic lymphocytic leukemia and unmutated immunoglobulin heavy-chain variable region gene (IGHV) have inferior survival from time of treatment in clinical studies. We assessed real-world outcomes based on mutational status and treatment regimen in a nationwide population-based cohort, comprising all 4,1...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.220194

    authors: Rotbain EC,Frederiksen H,Hjalgrim H,Rostgaard K,Egholm GJ,Zahedi B,Poulsen CB,Enggard L,da Cunha-Bang C,Niemann CU

    更新日期:2020-06-01 00:00:00

  • Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma.

    abstract::We investigated the role of single nucleotide polymorphisms in genes encoding for drug-metabolizing enzymes in 209 newly diagnosed multiple myeloma patients included in a clinical trial comparing single with double intensive therapy. We observed no significant association between polymorphisms in CYP3A4, CYP3A5, MDR1,...

    journal_title:Haematologica

    pub_type: 信件

    doi:10.3324/haematol.10618

    authors: Schilthuizen C,Broyl A,van der Holt B,de Knegt Y,Lokhorst H,Sonneveld P

    更新日期:2007-02-01 00:00:00

  • In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.

    abstract:BACKGROUND AND OBJECTIVES:Inhibition of soluble fibrinogen binding to activated platelets represents the target of pharmacologic approach with antagonists of the glycoprotein IIb/IIIa (GPIIb/IIIa) complex. In this study we assessed the effects of abciximab, a recombinant chimeric Fab fraction of the antibody against GP...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Rossi F,Rossi E,Pareti FI,Colli S,Tremoli E,Gallo L

    更新日期:2001-02-01 00:00:00

  • Study of hemostasis in pediatric patients with portal vein thrombosis.

    abstract::We describe the behavior of hemostatic variables in children with portal vein thrombosis (PVT) and in a control pediatric population. Hereditary protein C (PC) or protein S (PS) deficiency was not a etiologic factor for PVT in children. Minor signs of consumption of coagulation factors II, V, fibrinogen and hyperfibri...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Seixas CA,Hessel G,Siqueira LH,Machado TF,Gallizoni AM,Annichino-Bizzacchi JM

    更新日期:1998-10-01 00:00:00

  • Fibrinogen survival and fibrinopeptide A in acute leukemia.

    abstract::BACKGROUND. Hypofibrinogenemia and increased fibrin(ogen) degradation products in acute leukemia have been attributed to intravascular thrombin generation triggered by leukemic cells. However, the strict relationship between fibrinogen catabolism and turnover of fibrinopeptide A (FPA), which is a sensitive and specifi...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Castaman G,Galloni E,Dri AV,Rodeghiero F

    更新日期:1993-11-01 00:00:00

  • 1,25-Dihydroxyvitamin D3 in the treatment of idiopathic thrombocythemia and myelofibrosis.

    abstract::The effect of treatment with 1,25-dihydroxyvitamin D3 administered at the dose of 1.50-3.00 ug/day for at least 12 months was evaluated in three patients with idiopathic myelofibrosis and in five patients with idiopathic thrombocythemia. This treatment did not cause any significant change in the hematological values o...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Foa P,Maiolo AT,Cortellaro M,Ortolani S,Pogliani E,Deliliers GL,Iurlo A,Zocchi L,Gualdoni A,Polli E

    更新日期:1990-05-01 00:00:00

  • The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

    abstract::A retrospective, international, multicenter study was undertaken to assess: (i) the prognostic role of 'interim' positron emission tomography performed during treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in patients with Hodgkin lymphoma; and (ii) the reproducibility of the Deauville five-point s...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2013.103218

    authors: Gallamini A,Barrington SF,Biggi A,Chauvie S,Kostakoglu L,Gregianin M,Meignan M,Mikhaeel GN,Loft A,Zaucha JM,Seymour JF,Hofman MS,Rigacci L,Pulsoni A,Coleman M,Dann EJ,Trentin L,Casasnovas O,Rusconi C,Brice P,Bolis

    更新日期:2014-06-01 00:00:00

  • Aerobic glycolysis fuels platelet activation: small-molecule modulators of platelet metabolism as anti-thrombotic agents.

    abstract::Platelets are critical to arterial thrombosis, which underlies myocardial infarction and stroke. Activated platelets, regardless of the nature of their stimulus, initiate energy-intensive processes that sustain thrombus, while adapting to potential adversities of hypoxia and nutrient deprivation within the densely pac...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.205724

    authors: Kulkarni PP,Tiwari A,Singh N,Gautam D,Sonkar VK,Agarwal V,Dash D

    更新日期:2019-04-01 00:00:00

  • Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms.

    abstract::Most DNA methylation studies in classic Philadelphia-negative myeloproliferative neoplasms have been performed on a gene-by-gene basis. Therefore, a more comprehensive methylation profiling is needed to study the implications of this epigenetic marker in myeloproliferative neoplasms. Here, we have analyzed 71 chronic ...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2013.084160

    authors: Pérez C,Pascual M,Martín-Subero JI,Bellosillo B,Segura V,Delabesse E,Álvarez S,Larrayoz MJ,Rifón J,Cigudosa JC,Besses C,Calasanz MJ,Cross NC,Prósper F,Agirre X

    更新日期:2013-09-01 00:00:00

  • Myeloproliferative disease in patients with a history of multiple blood donations: a report of 8 cases.

    abstract:BACKGROUND:The clonal origin of myeloproliferative disorders has been clearly demonstrated and it is known that reactive thrombocytosis occurs as a non specific response to various inflammatory or neoplastic conditions. Only a few papers have discussed the topic of myeloproliferative diseases in blood donors. MATERIAL...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Randi ML,Rossi C,Barbone E,Cavatton G,Fabris F,Girolami A

    更新日期:1994-03-01 00:00:00

  • Predictive factors and impact of full donor T-cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.

    abstract::This study investigated the kinetics of CD3+-T cell chimerism (TCC) in 102 patients receiving reduced intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) from an HLA-identical sibling. Patients with full donor TCC at day 30 had a higher incidence of grade 2-4 acute GVHD compared to patients in m...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.10971

    authors: Mohty M,Avinens O,Faucher C,Viens P,Blaise D,Eliaou JF

    更新日期:2007-07-01 00:00:00

  • In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study.

    abstract::Eight elderly patients with relapsed or refractory acute myeloid leukemia were treated sequentially with recombinant human granulocyte colony-stimulating factor with rhG-CSF and Mylotarg. Priming with rhG-CSF in vivo induced an increase in the proportion of CD33+ cycling blasts. Four patients (50% ) achieved a complet...

    journal_title:Haematologica

    pub_type: 信件

    doi:

    authors: Leone G,Rutella S,Voso MT,Fianchi L,Scardocci A,Pagano L

    更新日期:2004-05-01 00:00:00

  • Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency.

    abstract:BACKGROUND:Protein S, which circulates in plasma in both free and bound forms, is an anticoagulant protein that stimulates activated protein C and tissue factor pathway inhibitor. Hereditary type I protein S deficiency (low total and low free protein S) is a well-established risk factor for venous thrombosis, whereas t...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2010.021923

    authors: Castoldi E,Maurissen LF,Tormene D,Spiezia L,Gavasso S,Radu C,Hackeng TM,Rosing J,Simioni P

    更新日期:2010-09-01 00:00:00

  • Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.

    abstract:BACKGROUND AND OBJECTIVES:Hydroxyurea (HU) is known to increase gamma-globin chain expression in postnatal life. The efficacy of HU treatment in thalassemia patients is still unclear. The aim of this study was to monitor treatment of a large cohort of patients with beta-thalassemia major in order to establish the respo...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章,多中心研究

    doi:

    authors: Yavarian M,Karimi M,Bakker E,Harteveld CL,Giordano PC

    更新日期:2004-10-01 00:00:00

  • Seven novel mutations of the UGT1A1 gene in patients with unconjugated hyperbilirubinemia.

    abstract::The aim of this study was to identify new pathogenic variations of the UGT1A1 gene in 11 patients diagnosed with neonatal unconjugated hyperbilirubinemia. We describe two cases in which clinically unapparent heterozygotic mutations in the UGT1A1 gene may become evident in combination with certain environmental conditi...

    journal_title:Haematologica

    pub_type: 信件

    doi:10.3324/haematol.10585

    authors: D'Apolito M,Marrone A,Servedio V,Vajro P,De Falco L,Iolascon A

    更新日期:2007-01-01 00:00:00

  • Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

    abstract::Anti-CD20-containing chemotherapy regimens have become the standard of care for patients with follicular lymphoma needing cytotoxic therapy. Four randomized trials demonstrated a clinical benefit for patients treated with rituximab. However, no long-term follow up (i.e. > 5 years) of these trials is yet available. Bet...

    journal_title:Haematologica

    pub_type: 杂志文章,随机对照试验

    doi:10.3324/haematol.2012.082412

    authors: Bachy E,Houot R,Morschhauser F,Sonet A,Brice P,Belhadj K,Cartron G,Audhuy B,Fermé C,Feugier P,Sebban C,Delwail V,Maisonneuve H,Le Gouill S,Lefort S,Brousse N,Foussard C,Salles G,Groupe d'Etude des Lymphomes de l'Adult

    更新日期:2013-07-01 00:00:00

  • Multivariate analysis of Hodgkin's disease prognosis. Fitness and use of a directly predictive equation.

    abstract::The main purpose of this work is to give methodologic details and further verification regarding the predictive system recently elaborated for Hodgkin's disease (HD) patients, by which, under standard accuracy and conventional treatment, patient survival can be directly estimated (within a given confidence interval) w...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Gobbi PG,Gobbi PG,Mazza P,Zinzani PL

    更新日期:1989-01-01 00:00:00

  • Pleiotropic anti-myeloma activity of ITF2357: inhibition of interleukin-6 receptor signaling and repression of miR-19a and miR-19b.

    abstract:BACKGROUND:The histone deacetylase inhibitor ITF2357 has potent cytotoxic activity in multiple myeloma in vitro and has entered clinical trials for this disease. DESIGN AND METHODS:In order to gain an overall view of the activity of ITF2357 and identify specific pathways that may be modulated by the drug, we performed...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2009.012088

    authors: Todoerti K,Barbui V,Pedrini O,Lionetti M,Fossati G,Mascagni P,Rambaldi A,Neri A,Introna M,Lombardi L,Golay J

    更新日期:2010-02-01 00:00:00

  • Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.

    abstract::The introduction and the extended clinical use of nilotinib in the first-line treatment of chronic myeloid leukemia have been based on company-sponsored trials. Independent confirmations are extremely important. We report an investigator-sponsored study of nilotinib 300 mg twice daily in 130 chronic myeloid leukemia p...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2016.144949

    authors: Castagnetti F,Breccia M,Gugliotta G,Martino B,D'Adda M,Stagno F,Carella AM,Avanzini P,Tiribelli M,Trabacchi E,Visani G,Gobbi M,Salvucci M,Levato L,Binotto G,Capalbo SF,Bochicchio MT,Soverini S,Cavo M,Martinelli G,

    更新日期:2016-10-01 00:00:00

  • Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas.

    abstract::Plasma levels of several soluble factors were assayed in 31 untreated patients with high-grade non-Hodgkin's lymphomas (NHL). The results showed statistically significant higher average levels of interleukin-2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-2 receptor (IL-2r) and transferrin receptor (...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Stasi R,Conforti M,Del Poeta G,Simone MD,Coppetelli U,Tribalto M,Cantonetti M,Perrotti A,Venditti A,Papa G

    更新日期:1992-11-01 00:00:00

  • Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma.

    abstract::Dickkopf-1 (DKK1), broadly expressed by tumor cells from human multiple myeloma (MM) and other cancers but absent from most normal tissues, may be an ideal target for immunotherapy. Our previous studies have shown that DKK1 (peptide)-specific cytotoxic T lymphocytes can effectively lyse primary MM cells in vitro. To d...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2019.236836

    authors: Li R,Zheng C,Wang Q,Bi E,Yang M,Hou J,Fu W,Yi Q,Qian J

    更新日期:2020-02-20 00:00:00

  • Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.

    abstract:BACKGROUND AND OBJECTIVES:Recent progress in the development of diagnostic techniques has greatly facilitated the monitoring of minimal residual disease (MRD) in patients with chronic myeloid leukemia (CML) after allogeneic bone marrow transplantation (BMT), the only curative treatment for this disease. The presence of...

    journal_title:Haematologica

    pub_type: 杂志文章,评审

    doi:

    authors: Román J,Alvarez MA,Torres A

    更新日期:2000-10-01 00:00:00

  • Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia.

    abstract::Mixed lineage leukemia (MLL/KMT2A) rearrangements (MLL-r) are one of the most frequent chromosomal aberrations in acute myeloid leukemia. We evaluated the function of Meningioma 1 (MN1), a co-factor of HOXA9 and MEIS1, in human and murine MLL-rearranged leukemia by CRISPR-Cas9 mediated deletion of MN1. MN1 was require...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2018.211201

    authors: Sharma A,Jyotsana N,Gabdoulline R,Heckl D,Kuchenbauer F,Slany RK,Ganser A,Heuser M

    更新日期:2020-05-01 00:00:00

  • HTLV-I positive adult T-cell leukaemia-lymphoma: report of a typical case from Italy.

    abstract::A case of acute adult T-cell leukemia-lymphoma (ATLL) was observed in northeast Italy, presenting with fever, lymphadenomegaly, splenomegaly, hypercalcemia and renal failure. Leukaemic cells were morphologically typical, expressed a T-cell CD4+ phenotype, did not display any helper functions, and grew in vitro under s...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:

    authors: Fanin R,Minutillo S,D'Agaro P,Raspadori D,Tassinari A,Tazzari P,Testoni N,Damiani D,Gallizia C,Michieli M

    更新日期:1990-07-01 00:00:00

  • IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis.

    abstract:BACKGROUND:Myelodysplastic syndromes are a heterogeneous group of hematopoietic stem cell disorders with a high propensity to transform into acute myeloid leukemia. Heterozygous missense mutations in IDH1 at position R132 and in IDH2 at positions R140 and R172 have recently been reported in acute myeloid leukemia. Howe...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2010.025494

    authors: Thol F,Weissinger EM,Krauter J,Wagner K,Damm F,Wichmann M,Göhring G,Schumann C,Bug G,Ottmann O,Hofmann WK,Schlegelberger B,Ganser A,Heuser M

    更新日期:2010-10-01 00:00:00

  • Telomere length is associated with disease severity and declines with age in dyskeratosis congenita.

    abstract:BACKGROUND:Dyskeratosis congenita is a cancer-prone bone marrow failure syndrome caused by aberrations in telomere biology. DESIGN AND METHODS:We studied 65 patients with dyskeratosis congenita and 127 unaffected relatives. Telomere length was measured by automated multicolor flow fluorescence in situ hybridization in...

    journal_title:Haematologica

    pub_type: 临床试验,杂志文章

    doi:10.3324/haematol.2011.055269

    authors: Alter BP,Rosenberg PS,Giri N,Baerlocher GM,Lansdorp PM,Savage SA

    更新日期:2012-03-01 00:00:00

  • Position 156 influences the peptide repertoire and tapasin dependency of human leukocyte antigen B*44 allotypes.

    abstract:BACKGROUND:Polymorphic differences between donor and recipient human leukocyte antigen class I molecules can result in graft-versus-host disease due to distinct peptide presentation. As part of the peptide-loading complex, tapasin plays an important role in selecting peptides from the pool of potential ligands. Class I...

    journal_title:Haematologica

    pub_type: 杂志文章

    doi:10.3324/haematol.2011.046037

    authors: Badrinath S,Saunders P,Huyton T,Aufderbeck S,Hiller O,Blasczyk R,Bade-Doeding C

    更新日期:2012-01-01 00:00:00